Michelle Gilson
Stock Analyst at Morgan Stanley
(1.08)
# 3,883
Out of 5,241 analysts
32
Total ratings
31.03%
Success rate
-6.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Michelle Gilson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VIR Vir Biotechnology | Maintains: Overweight | $20 → $24 | $8.79 | +173.04% | 5 | Feb 24, 2026 | |
| CORT Corcept Therapeutics | Initiates: Buy | $30 | $56.37 | -46.78% | 1 | Feb 2, 2022 | |
| RZLT Rezolute | Maintains: Buy | $30 → $17 | $3.34 | +408.98% | 2 | Nov 29, 2021 | |
| ASND Ascendis Pharma | Maintains: Buy | $190 → $196 | $240.43 | -18.48% | 5 | Jun 1, 2021 | |
| TVTX Travere Therapeutics | Maintains: Buy | $48 → $45 | $42.59 | +5.66% | 3 | May 27, 2021 | |
| STOK Stoke Therapeutics | Maintains: Buy | $72 → $76 | $30.08 | +152.66% | 4 | Mar 11, 2021 | |
| BMRN BioMarin Pharmaceutical | Maintains: Buy | $95 → $91 | $51.81 | +75.64% | 12 | Mar 1, 2021 |
Vir Biotechnology
Feb 24, 2026
Maintains: Overweight
Price Target: $20 → $24
Current: $8.79
Upside: +173.04%
Corcept Therapeutics
Feb 2, 2022
Initiates: Buy
Price Target: $30
Current: $56.37
Upside: -46.78%
Rezolute
Nov 29, 2021
Maintains: Buy
Price Target: $30 → $17
Current: $3.34
Upside: +408.98%
Ascendis Pharma
Jun 1, 2021
Maintains: Buy
Price Target: $190 → $196
Current: $240.43
Upside: -18.48%
Travere Therapeutics
May 27, 2021
Maintains: Buy
Price Target: $48 → $45
Current: $42.59
Upside: +5.66%
Stoke Therapeutics
Mar 11, 2021
Maintains: Buy
Price Target: $72 → $76
Current: $30.08
Upside: +152.66%
BioMarin Pharmaceutical
Mar 1, 2021
Maintains: Buy
Price Target: $95 → $91
Current: $51.81
Upside: +75.64%